about-image

OUR INVESTORS

GA Glybera Alipogene Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life threatening illnesses around the world. At GA we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.

Glybera Alipogene portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Glybera Alipogene was founded in 1981 in Basel, Switzerland Since then, we have grown to become one of the world’s largest biopharmaceutical companies, with 8,073 employees across six continents.

Glybera Alipogene was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healthcare. Two-thirds of our Research and Development projects are being developed with companion diagnostics As a global healthcare company, we take on some of the world’s biggest healthcare challenges.

OUR PRODUCTS

We pride ourselves with internationally recognised and accepted products

service-1

VACCINES

Our vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across over 150 countries

See More

service-2

HEALTHCARE PRODUCTS

Our consumer healthcare business has a portfolio of some of the world’s most trusted and best selling products in Pain Relief, Oral health, Respiratory, Nutrition and Skin health

See More

service-3

VIIV HEALTHCARE

ViiV Healthcare is an independent, global specialist HIV company dedicated to delivering innovative new options for the care and treatment of people living with HIV/AIDS

See More

17483
Happy Customers
465
Products
96
Vaccines
345
Treatments